The US Food and Drug Administration on Tuesday granted accelerated approval to GSK’s therapy for a rare form of advanced lung cancer in patients whose disease has worsened on existing drugs, Reuters reported. The once daily oral therapy, neladalkib, sold under the brand name Nelkarmi, is approved for patients with a type of non-small cell lung cancer whose disease has progressed after treatment with ALK tyrosine kinase inhibitors, a class of targeted drugs that block an abnormal protein driving tumour growth.
Neladalkib was one of two late stage lung cancer drugs GSK gained through its $10.6 billion acquisition of Nuvalent, completed in July; the other, Jideytro, won FDA approval the same month. The application rested on a trial in which the drug shrank tumours, including tumours that had spread to the brain, in previously treated patients, and the drug is also being studied against Roche’s Alecensa as a first line treatment in a late stage trial.